Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and ...

Panel recommends ICMR to hold inter-ministerial consultation on patent duration: Gireesh Babu, New Delhi Saturday, March 15, 2025, 08:00 Hrs [IST] The Parliamentary Panel on Healt ...

Leap Therapeutics (NASDAQ:LPTX – Get Free Report) is anticipated to announce its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0 ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

Izuchukwu Okpalanwaka is a pharmacist and a doctoral researcher at the Texas Tech University Health Science Center (TTUHSC), United States. He is also the co-founder of the Tropical Medical Oncology ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different ...

F or patients diagnosed with stage 4 cancer, a condition often accompanied by limited treatment options and grim prognoses, ...